Esperion Therapeutics, Inc. (0IIM.L)
USD 2.27
(-8.85%)
USD 2.27
(-8.85%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 205.79 Million USD | -17.0% |
| 2022 | 247.93 Million USD | -35.02% |
| 2021 | 381.59 Million USD | 8.02% |
| 2020 | 353.25 Million USD | 64.73% |
| 2019 | 214.44 Million USD | 49.49% |
| 2018 | 143.45 Million USD | -48.37% |
| 2017 | 277.83 Million USD | 13.3% |
| 2016 | 245.21 Million USD | -17.04% |
| 2015 | 295.57 Million USD | 106.2% |
| 2014 | 143.34 Million USD | 83.08% |
| 2013 | 78.29 Million USD | 970.69% |
| 2012 | 7.31 Million USD | 235.47% |
| 2011 | 2.17 Million USD | 0.0% |
| 2002 | 51.4 Million USD | -34.38% |
| 2001 | 78.34 Million USD | 0.59% |
| 2000 | 77.87 Million USD | 873.6% |
| 1999 | 7.99 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 352.31 Million USD | -5.56% |
| 2024 Q1 | 373.06 Million USD | 81.28% |
| 2023 Q3 | 221.3 Million USD | -5.68% |
| 2023 FY | 205.79 Million USD | -17.0% |
| 2023 Q4 | 205.79 Million USD | -7.01% |
| 2023 Q2 | 234.62 Million USD | -6.83% |
| 2023 Q1 | 251.81 Million USD | 1.56% |
| 2022 Q3 | 312.82 Million USD | 2.91% |
| 2022 FY | 247.93 Million USD | -35.02% |
| 2022 Q4 | 247.93 Million USD | -20.74% |
| 2022 Q2 | 303.98 Million USD | -11.34% |
| 2022 Q1 | 342.85 Million USD | -10.15% |
| 2021 Q4 | 381.59 Million USD | 69.4% |
| 2021 FY | 381.59 Million USD | 8.02% |
| 2021 Q3 | 225.25 Million USD | -19.68% |
| 2021 Q2 | 280.46 Million USD | 0.67% |
| 2021 Q1 | 278.6 Million USD | -21.13% |
| 2020 Q1 | 179.64 Million USD | -16.23% |
| 2020 Q3 | 250.96 Million USD | -24.03% |
| 2020 FY | 353.25 Million USD | 64.73% |
| 2020 Q2 | 330.35 Million USD | 83.89% |
| 2020 Q4 | 353.25 Million USD | 40.76% |
| 2019 Q3 | 255.27 Million USD | -17.34% |
| 2019 Q4 | 214.44 Million USD | -15.99% |
| 2019 FY | 214.44 Million USD | 49.49% |
| 2019 Q1 | 236.48 Million USD | 64.85% |
| 2019 Q2 | 308.81 Million USD | 30.59% |
| 2018 Q3 | 174.03 Million USD | -17.47% |
| 2018 Q1 | 244.18 Million USD | -12.11% |
| 2018 FY | 143.45 Million USD | -48.37% |
| 2018 Q4 | 143.45 Million USD | -17.57% |
| 2018 Q2 | 210.88 Million USD | -13.64% |
| 2017 Q4 | 277.83 Million USD | -11.26% |
| 2017 Q2 | 185.24 Million USD | -13.69% |
| 2017 Q1 | 214.61 Million USD | -12.48% |
| 2017 FY | 277.83 Million USD | 13.3% |
| 2017 Q3 | 313.09 Million USD | 69.02% |
| 2016 Q1 | 286.03 Million USD | -3.23% |
| 2016 FY | 245.21 Million USD | -17.04% |
| 2016 Q4 | 245.21 Million USD | -7.04% |
| 2016 Q2 | 277.46 Million USD | -3.0% |
| 2016 Q3 | 263.79 Million USD | -4.93% |
| 2015 Q4 | 295.57 Million USD | -3.53% |
| 2015 FY | 295.57 Million USD | 106.2% |
| 2015 Q1 | 325.22 Million USD | 126.88% |
| 2015 Q2 | 315.95 Million USD | -2.85% |
| 2015 Q3 | 306.39 Million USD | -3.03% |
| 2014 Q1 | 70.22 Million USD | -10.31% |
| 2014 Q3 | 60.53 Million USD | -12.64% |
| 2014 Q4 | 143.34 Million USD | 136.81% |
| 2014 FY | 143.34 Million USD | 83.08% |
| 2014 Q2 | 69.28 Million USD | -1.33% |
| 2013 Q1 | 22.26 Million USD | 204.48% |
| 2013 Q2 | 19.53 Million USD | -12.27% |
| 2013 Q3 | 86.57 Million USD | 343.2% |
| 2013 Q4 | 78.29 Million USD | -9.57% |
| 2013 FY | 78.29 Million USD | 970.69% |
| 2012 Q4 | 7.31 Million USD | 0.0% |
| 2012 FY | 7.31 Million USD | 235.47% |
| 2011 FY | 2.17 Million USD | 0.0% |
| 2003 Q1 | 44.27 Million USD | -13.88% |
| 2003 Q3 | 99.43 Million USD | 160.61% |
| 2003 Q2 | 38.15 Million USD | -13.82% |
| 2002 FY | 51.4 Million USD | -34.38% |
| 2002 Q2 | 64.3 Million USD | -10.96% |
| 2002 Q3 | 57.08 Million USD | -11.22% |
| 2002 Q1 | 72.22 Million USD | -7.81% |
| 2002 Q4 | 51.4 Million USD | -9.95% |
| 2001 Q2 | 68.28 Million USD | -5.69% |
| 2001 Q4 | 78.34 Million USD | -7.8% |
| 2001 FY | 78.34 Million USD | 0.59% |
| 2001 Q1 | 72.39 Million USD | -7.04% |
| 2001 Q3 | 84.96 Million USD | 24.43% |
| 2000 Q1 | 30.48 Million USD | 0.0% |
| 2000 FY | 77.87 Million USD | 873.6% |
| 2000 Q2 | 25.87 Million USD | -15.13% |
| 2000 Q3 | 82.87 Million USD | 220.25% |
| 2000 Q4 | 77.87 Million USD | -6.03% |
| 1999 FY | 7.99 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | 58.771% |
| Dynavax Technologies Corporation | 997.09 Million USD | 79.36% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 85.394% |
| Perrigo Company plc | 10.8 Billion USD | 98.096% |
| Illumina, Inc. | 10.11 Billion USD | 97.965% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.792% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 73.628% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.746% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.229% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 7.51% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.378% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -213.284% |
| Waters Corporation | 4.62 Billion USD | 95.552% |
| Biogen Inc. | 26.84 Billion USD | 99.233% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -24.483% |
| Evolus, Inc. | 188.99 Million USD | -8.888% |
| Adicet Bio, Inc. | 207.29 Million USD | 0.723% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -63.533% |
| bluebird bio, Inc. | 619.16 Million USD | 66.762% |
| FibroGen, Inc. | 423.52 Million USD | 51.409% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 98.088% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -627.904% |
| Homology Medicines, Inc. | 47.05 Million USD | -337.333% |
| Geron Corporation | 394.07 Million USD | 47.778% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 94.627% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 73.544% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 82.832% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 44.152% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 84.181% |
| Zoetis Inc. | 14.28 Billion USD | 98.559% |
| Abeona Therapeutics Inc. | 64 Million USD | -221.546% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 93.867% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 96.992% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.095% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -267.828% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 93.117% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -24.345% |
| Verastem, Inc. | 149.71 Million USD | -37.456% |
| Nektar Therapeutics | 398.03 Million USD | 48.297% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 65.015% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -4.251% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 93.696% |
| OPKO Health, Inc. | 2.01 Billion USD | 89.77% |
| Exelixis, Inc. | 2.94 Billion USD | 93.006% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 93.671% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 66.888% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -33.3% |
| uniQure N.V. | 831.68 Million USD | 75.256% |
| Imunon, Inc. | 21.91 Million USD | -838.933% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 80.386% |
| Insmed Incorporated | 1.32 Billion USD | 84.525% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 88.127% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 78.039% |
| TG Therapeutics, Inc. | 329.58 Million USD | 37.559% |
| Incyte Corporation | 6.78 Billion USD | 96.966% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 88.784% |